These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 18041885)

  • 1. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin.
    Doria C; Bodzin AS; Vaccino S; Daskalakis C; Krawitz S; Ramirez CB
    Clin Transplant; 2011; 25(4):569-75. PubMed ID: 20662881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of targeted antifungal prophylaxis in heart transplant recipients at high risk for early invasive fungal infection.
    Tissot F; Pascual M; Hullin R; Yerly P; Tozzi P; Meylan P; Manuel O
    Transplantation; 2014 Jun; 97(11):1192-7. PubMed ID: 24521774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
    El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
    Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
    Winston DJ; Bartoni K; Territo MC; Schiller GJ
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients.
    O'Donnell MR; Schmidt GM; Tegtmeier BR; Faucett C; Fahey JL; Ito J; Nademanee A; Niland J; Parker P; Smith EP
    J Clin Oncol; 1994 Apr; 12(4):827-34. PubMed ID: 8151325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
    Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
    Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
    Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
    Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
    Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
    Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.
    Saliba F; Pascher A; Cointault O; Laterre PF; Cervera C; De Waele JJ; Cillo U; Langer RM; Lugano M; Göran-Ericzon B; Phillips S; Tweddle L; Karas A; Brown M; Fischer L; ;
    Clin Infect Dis; 2015 Apr; 60(7):997-1006. PubMed ID: 25520332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
    Sun HY; Cacciarelli TV; Singh N
    Transplantation; 2013 Sep; 96(6):573-8. PubMed ID: 23842191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.